Beyond viral vectors: Hao Wu on non-viral delivery, immune-evasive DNA, and what the field still needs to prove

“I am hopeful that we will see more clinical applications of both viral and non‑viral gene‑writing approaches delivering therapeutic outcomes in the years to come.”

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights , speaks with Hao Wu, co-founder and CSO of Full Circles Therapeutics, about the evolving landscape of non‑viral delivery in cell and gene therapy, the development of the INSTALL platform for immune‑evasive kilobase gene writing, and the outlook for non‑viral approaches as alternatives to viral vectors.

Please enter your email to access content Read now